A partial agonist of PPARγ
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Balaglitazone

Item No. 28866

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]phenyl]methyl]-2,4-thiazolidinedione
CAS Number
199113-98-9
Synonyms
  • DRF 2593
Molecular Formula
C20H17N3O4S
Formula Weight
395.4
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml
λmax
226 nm
SMILES
O=C1N(C)C(COC2=CC=C(CC3SC(NC3=O)=O)C=C2)=NC4=CC=CC=C41
InChi Code
InChI=1S/C20H17N3O4S/c1-23-17(21-15-5-3-2-4-14(15)19(23)25)11-27-13-8-6-12(7-9-13)10-16-18(24)22-20(26)28-16/h2-9,16H,10-11H2,1H3,(H,22,24,26)
InChi Key
IETKPTYAGKZLKY-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $53

    Add

    5 mg

    $212

    Add

    10 mg

    $317

    Add

    25 mg

    $462

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Balaglitazone is a partial agonist of peroxisome proliferator-activated receptor γ (PPARγ; EC50 = 1.351 μM in a transactivation assay).1 It decreases non-fasting plasma glucose levels in diabetic db/db mice (ED90 = 3 mg/kg per day). Balaglitazone (5 and 10 mg/kg per day) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in diet-induced obese rats.2 In doxorubicin-resistant K562 human myelogenous leukemia cells, balaglitazone (25 μM) decreases P-glycoprotein (P-gp) levels, increases intracellular accumulation of the P-gp substrate rhodamine 123 (Item No. 16672), and sensitizes cells to doxorubicin (Item No. 15007).3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Larsen, P.J., Lykkegaard, K., Larsen, L.K., et al. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-γ) agonist balaglitazone. Eur. J. Pharmacol. 596(1-3), 173-179 (2008).

    2. Henriksen, K., Byrjalsen, I., Nielsen, R.H., et al. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats. Eur. J. Pharmacol. 616(1-3), 340-345 (2009).

    3. Yousefi, B., Azimi, A., Majidinia, M., et al. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells. Tumour Biol. 39(10), (2017).